ATE504293T1 - Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung - Google Patents

Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung

Info

Publication number: ATE504293T1
Authority: AT; Austria
Prior art keywords: treatment; bipolar disorder; carbostyril derivatives; subtype agonists; substituted carbostyril
Prior art date: 2001-01-29

Application number

AT06015782T

Other languages

English (en)

Inventor

Yasufumi Uwahodo

Shaun Jordan

Tetsuro Kikuchi

Katsura Tottori

Tsuyoshi Hirose

Original Assignee

Otsuka Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-01-29

Filing date

2002-01-29

Publication date

2011-04-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25087808&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE504293(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-01-29 Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE504293T1 publication Critical patent/ATE504293T1/de

Links

102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 title 1
101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 title 1
208000020925 Bipolar disease Diseases 0.000 title 1
239000000556 agonist Substances 0.000 title 1
LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical class C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Hematology (AREA)
Otolaryngology (AREA)
Diabetes (AREA)
Child & Adolescent Psychology (AREA)
Gynecology & Obstetrics (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Quinoline Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

AT06015782T 2001-01-29 2002-01-29 Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung ATE504293T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US77021001A	2001-01-29	2001-01-29

Publications (1)

Publication Number	Publication Date
ATE504293T1 true ATE504293T1 (de)	2011-04-15

Family

ID=25087808

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
AT05023971T ATE362763T1 (de)	2001-01-29	2002-01-29	Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
AT02716434T ATE322894T1 (de)	2001-01-29	2002-01-29	Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
AT06015782T ATE504293T1 (de)	2001-01-29	2002-01-29	Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten zur behandlung von bipolarer störung

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
AT05023971T ATE362763T1 (de)	2001-01-29	2002-01-29	Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten
AT02716434T ATE322894T1 (de)	2001-01-29	2002-01-29	Substituierte carbostyrilderivate als 5-ht1a- subtyp agonisten

Country Status (19)

Country	Link
EP (3)	EP1712225B1 (de)
JP (4)	JP4178032B2 (de)
KR (5)	KR100713607B1 (de)
CN (3)	CN100450485C (de)
AR (4)	AR032641A1 (de)
AT (3)	ATE362763T1 (de)
AU (4)	AU2002226752C1 (de)
BR (1)	BR0206237A (de)
CA (2)	CA2700314C (de)
CY (3)	CY1105631T1 (de)
DE (3)	DE60210581T2 (de)
DK (3)	DK1621198T3 (de)
ES (3)	ES2286755T3 (de)
MX (2)	MXPA03006603A (de)
MY (1)	MY129355A (de)
PH (1)	PH12014500937A1 (de)
PT (3)	PT1712225E (de)
TW (2)	TWI302832B (de)
WO (1)	WO2002060423A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7053092B2 (en)	2001-01-29	2006-05-30	Otsuka Pharmaceutical Co., Ltd.	5-HT1a receptor subtype agonist
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
AR033485A1 (es)	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en)	2001-09-25	2014-04-22	Otsuka Pharmaceutical Co., Ltd.	Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
DE10148233A1 (de) *	2001-09-28	2003-04-10	Boehringer Ingelheim Pharma	Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
MXPA05000294A (es) *	2002-07-30	2005-08-19	Peter Migaly	Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
AR042806A1 (es) *	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
EP1575590B1 (de) *	2002-12-27	2007-10-24	Otsuka Pharmaceutical Co., Ltd.	Carbostyril-derivate mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von gemütskrankheiten
PT1626721T (pt)	2003-05-23	2017-02-28	Otsuka Pharma Co Ltd	Derivados de carbostirilo e estabilizadores de humor para tratar distúrbios de humor
US7160888B2 (en)	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
FR2865650B1 (fr) *	2004-01-30	2008-06-13	Biocortech	Utilisation du 14,15 dihydro 20,21-dinoreburnamenin14-ol pour traiter et/ou prevenir les depressions majeures et les desordres du cycle veille-sommeil
WO2006090273A2 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
US8227476B2 (en) *	2005-08-03	2012-07-24	Sprout Pharmaceuticals, Inc.	Use of flibanserin in the treatment of obesity
TW200848041A (en)	2007-03-30	2008-12-16	Otsuka Pharma Co Ltd	A medicament for treating schizophrenia comprising cilostazol
GB2456183A (en)	2008-01-04	2009-07-08	Gw Pharma Ltd	Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
JP2009286740A (ja) *	2008-05-30	2009-12-10	Otsuka Pharmaceut Co Ltd	アリピプラゾールを含有する逆耐性抑制剤
EP2338873A1 (de)	2009-12-22	2011-06-29	Gmeiner, Peter	Neue Aminotetralinderivate
AR090245A1 (es)	2012-03-06	2014-10-29	Otsuka Pharma Co Ltd	Preparacion solida oral de liberacion sostenida, metodo de preparacion
JOP20200109A1 (ar)	2012-04-23	2017-06-16	Otsuka Pharma Co Ltd	مستحضر قابل للحقن

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS54130587A (en) *	1978-03-30	1979-10-09	Otsuka Pharmaceut Co Ltd	Carbostyryl derivative
JPS5646812A (en) *	1979-09-27	1981-04-28	Otsuka Pharmaceut Co Ltd	Central nervous system depressant
DE3721799C2 (de)	1986-07-01	1993-12-23	Mitsubishi Electric Corp	Integrierte Redox-Bauelementschaltung und Verfahren zum Herstellen
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5006528A (en) *	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
WO1992020655A1 (en) *	1991-05-20	1992-11-26	The Upjohn Company	Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
US5532240A (en) *	1991-12-26	1996-07-02	Yoshitomi Pharmaceutical Industries, Ltd.	Condensed thiophene compound and pharmaceutical use thereof
AU5446894A (en) *	1992-10-23	1994-05-24	New York University	Functional interactions between glial s-100b and central nervous system serotonergic neurons
DK148292D0 (da) *	1992-12-09	1992-12-09	Lundbeck & Co As H	Forbindelser
JP2959615B2 (ja) *	1993-06-24	1999-10-06	吉富製薬株式会社	縮合型チオフェン化合物およびその医薬用途
JPH09291034A (ja) *	1996-02-27	1997-11-11	Yoshitomi Pharmaceut Ind Ltd	縮合ピリジン化合物およびその医薬としての用途
US5688950A (en) *	1996-04-23	1997-11-18	Neurogen Corporation	Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
CA2252895C (en) *	1996-05-07	2002-08-20	Pfizer Inc.	Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (=ziprasidone), its preparation and its use as dopamine d2 antagonist
JP4012994B2 (ja) *	1996-05-08	2007-11-28	大塚製薬株式会社	抗不安薬
CA2264080A1 (en) *	1996-08-27	1998-03-05	Richard Eric Mewshaw	4-aminoethoxy indoles as dopamin d2 agonists and as 5ht1a ligands
CA2317515A1 (en) *	1998-02-03	1999-08-05	Frances Christy Nelson	Oxazole derivatives as serotonin-1a receptor agonists
EP1073636A1 (de) *	1998-04-13	2001-02-07	American Home Products Corporation	4-amino-(ethylamino)-oxindol dopamin autorezeptor agoniste
JPH11335286A (ja) *	1998-05-25	1999-12-07	Mitsui Chem Inc	ドーパミン拮抗薬の効果増強剤
AR032641A1 (es) *	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
DE60234873D1 (de) *	2001-06-19	2010-02-04	Norbert Mueller	Verwendung von COX-2 Inhibitoren zur Behandlung von affectiven Störungen
AR033485A1 (es) *	2001-09-25	2003-12-26	Otsuka Pharma Co Ltd	Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma

2002
- 2002-01-15 AR ARP020100118A patent/AR032641A1/es not_active Application Discontinuation
- 2002-01-25 TW TW091101289A patent/TWI302832B/zh not_active IP Right Cessation
- 2002-01-25 TW TW093127321A patent/TWI331919B/zh not_active IP Right Cessation
- 2002-01-26 MY MYPI20020297A patent/MY129355A/en unknown
- 2002-01-29 AU AU2002226752A patent/AU2002226752C1/en not_active Expired
- 2002-01-29 WO PCT/JP2002/000626 patent/WO2002060423A2/en not_active Ceased
- 2002-01-29 DE DE60210581T patent/DE60210581T2/de not_active Expired - Lifetime
- 2002-01-29 MX MXPA03006603A patent/MXPA03006603A/es active IP Right Grant
- 2002-01-29 AT AT05023971T patent/ATE362763T1/de active
- 2002-01-29 JP JP2002560616A patent/JP4178032B2/ja not_active Expired - Lifetime
- 2002-01-29 PT PT06015782T patent/PT1712225E/pt unknown
- 2002-01-29 AT AT02716434T patent/ATE322894T1/de active
- 2002-01-29 MX MX2011010975A patent/MX344556B/es unknown
- 2002-01-29 KR KR1020067014046A patent/KR100713607B1/ko not_active Expired - Lifetime
- 2002-01-29 DK DK05023971T patent/DK1621198T3/da active
- 2002-01-29 KR KR1020077010561A patent/KR100825705B1/ko not_active Expired - Lifetime
- 2002-01-29 KR KR1020067005164A patent/KR100763288B1/ko not_active Ceased
- 2002-01-29 ES ES05023971T patent/ES2286755T3/es not_active Expired - Lifetime
- 2002-01-29 KR KR1020057019896A patent/KR100653591B1/ko not_active Expired - Lifetime
- 2002-01-29 AT AT06015782T patent/ATE504293T1/de active
- 2002-01-29 EP EP06015782A patent/EP1712225B1/de not_active Revoked
- 2002-01-29 EP EP02716434A patent/EP1355639B1/de not_active Expired - Lifetime
- 2002-01-29 CN CNB2005100228288A patent/CN100450485C/zh not_active Expired - Lifetime
- 2002-01-29 ES ES02716434T patent/ES2261652T3/es not_active Expired - Lifetime
- 2002-01-29 DK DK06015782.3T patent/DK1712225T3/da active
- 2002-01-29 DE DE60220325T patent/DE60220325T2/de not_active Expired - Lifetime
- 2002-01-29 DK DK02716434T patent/DK1355639T3/da active
- 2002-01-29 KR KR1020037008565A patent/KR100601073B1/ko not_active Expired - Lifetime
- 2002-01-29 BR BR0206237-2A patent/BR0206237A/pt not_active Application Discontinuation
- 2002-01-29 ES ES06015782T patent/ES2363366T3/es not_active Expired - Lifetime
- 2002-01-29 PT PT02716434T patent/PT1355639E/pt unknown
- 2002-01-29 CN CNB028035518A patent/CN1239154C/zh not_active Expired - Lifetime
- 2002-01-29 CA CA2700314A patent/CA2700314C/en not_active Expired - Lifetime
- 2002-01-29 CN CNA2006100943881A patent/CN1879624A/zh active Pending
- 2002-01-29 EP EP05023971A patent/EP1621198B1/de not_active Revoked
- 2002-01-29 PT PT05023971T patent/PT1621198E/pt unknown
- 2002-01-29 CA CA2429496A patent/CA2429496C/en not_active Expired - Lifetime
- 2002-01-29 DE DE60239711T patent/DE60239711D1/de not_active Expired - Lifetime
2005
- 2005-04-27 AU AU2005201772A patent/AU2005201772C1/en not_active Expired
2006
- 2006-06-28 CY CY20061100884T patent/CY1105631T1/el unknown
2007
- 2007-04-17 AU AU2007201701A patent/AU2007201701B2/en not_active Expired
- 2007-07-09 JP JP2007179275A patent/JP4896831B2/ja not_active Expired - Lifetime
- 2007-08-20 CY CY20071101093T patent/CY1108031T1/el unknown
2009
- 2009-10-29 AU AU2009233591A patent/AU2009233591B2/en not_active Expired
2010
- 2010-12-28 AR ARP100104973A patent/AR079761A2/es not_active Application Discontinuation
2011
- 2011-04-08 AR ARP110101189A patent/AR080849A2/es not_active Application Discontinuation
- 2011-04-18 CY CY20111100391T patent/CY1111392T1/el unknown
- 2011-06-15 JP JP2011133033A patent/JP2011184460A/ja active Pending
- 2011-06-15 JP JP2011133032A patent/JP5683010B2/ja not_active Expired - Lifetime
2014
- 2014-04-28 PH PH12014500937A patent/PH12014500937A1/en unknown
2015
- 2015-03-13 AR ARP150100766A patent/AR099754A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
ATE322894T1 (de)	2006-04-15
AR080849A2 (es)	2012-05-09
EP1712225B1 (de)	2011-04-06
KR20050107822A (ko)	2005-11-15
DE60210581D1 (en)	2006-05-24
HK1091403A1 (zh)	2007-01-19
PT1712225E (pt)	2011-04-18
MY129355A (en)	2007-03-30
EP1712225A1 (de)	2006-10-18
JP4178032B2 (ja)	2008-11-12
EP1355639B1 (de)	2006-04-12
CN100450485C (zh)	2009-01-14
TWI302832B (en)	2008-11-11
JP5683010B2 (ja)	2015-03-11
MX344556B (es)	2016-12-20
CN1239154C (zh)	2006-02-01
AU2005201772C1 (en)	2010-06-03
DK1355639T3 (da)	2006-08-14
PT1621198E (pt)	2007-06-08
ES2261652T3 (es)	2006-11-16
KR100713607B1 (ko)	2007-05-02
EP1621198A2 (de)	2006-02-01
JP2011184460A (ja)	2011-09-22
ES2363366T3 (es)	2011-08-02
AR079761A2 (es)	2012-02-15
AU2009233591B2 (en)	2011-10-20
CY1105631T1 (el)	2010-12-22
CA2429496A1 (en)	2002-08-08
JP2004517937A (ja)	2004-06-17
EP1355639A2 (de)	2003-10-29
AU2007201701B2 (en)	2010-06-17
PH12014500937A1 (en)	2015-09-21
AU2002226752B2 (en)	2005-03-17
DE60220325T2 (de)	2008-01-17
CN1879624A (zh)	2006-12-20
AU2005201772B2 (en)	2007-05-17
DE60220325D1 (de)	2007-07-05
KR100601073B1 (ko)	2006-07-19
EP1621198B1 (de)	2007-05-23
DK1712225T3 (da)	2011-06-20
AU2009233591A1 (en)	2009-11-19
HK1061805A1 (en)	2004-10-08
JP2011225587A (ja)	2011-11-10
CY1111392T1 (el)	2015-08-05
KR100825705B1 (ko)	2008-04-29
KR100763288B1 (ko)	2007-10-04
AU2002226752C1 (en)	2010-02-18
AR032641A1 (es)	2003-11-19
KR20060028485A (ko)	2006-03-29
CY1108031T1 (el)	2013-09-04
DK1621198T3 (da)	2007-09-24
KR100653591B1 (ko)	2006-12-05
AR099754A2 (es)	2016-08-17
JP2007297405A (ja)	2007-11-15
EP1621198A3 (de)	2006-04-12
KR20070065425A (ko)	2007-06-22
ES2286755T3 (es)	2007-12-01
AU2005201772A1 (en)	2005-05-19
CN1813745A (zh)	2006-08-09
MXPA03006603A (es)	2004-02-12
JP4896831B2 (ja)	2012-03-14
CA2700314A1 (en)	2002-08-08
ATE362763T1 (de)	2007-06-15
AU2007201701A1 (en)	2007-05-10
DE60210581T2 (de)	2007-04-05
DE60239711D1 (de)	2011-05-19
WO2002060423A3 (en)	2003-04-10
KR20060085260A (ko)	2006-07-26
CN1484524A (zh)	2004-03-24
KR20030065570A (ko)	2003-08-06
BR0206237A (pt)	2003-12-23
PT1355639E (pt)	2006-06-30
TWI331919B (en)	2010-10-21
TW200522960A (en)	2005-07-16
WO2002060423A2 (en)	2002-08-08
CA2700314C (en)	2012-04-24
CA2429496C (en)	2010-10-19

Legal Events

Date

Code

Title

Description

2011-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1712225

Country of ref document: EP

Publication	Publication Date	Title
DE60239711D1 (de)	2011-05-19	Substituierte Carbostyrilderivate als 5-HT1A-Subtyp Agonisten zur Behandlung von bipolarer Störung
DE60219292D1 (de)	2007-05-16	Pyrazolderivate zur behandlung von hiv
DE60234760D1 (de)	2010-01-28	Phenylindole zur behandlung von hiv
DE60019473D1 (de)	2005-05-19	(S,S)-Reboxetin zur Behandlung von peripheren Neuropathien
ATE401076T1 (de)	2008-08-15	Chinolinderivate als glucokinase liganden
ATE339418T1 (de)	2006-10-15	Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen
BR0014352A (pt)	2002-06-11	Cetoenóis espirocìclicos substituìdos por trifluormetila
NO20052580D0 (no)	2005-05-27	Blandinger for behandling av infeksjon av Flavivirida viruser
ATE455092T1 (de)	2010-01-15	Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE60206198D1 (de)	2005-10-20	Tetrahydrochinolinderivate als muscarinische agonisten
DE60003863D1 (de)	2003-08-21	Dioxocyclopentylhydroxamsäure
DE60212146D1 (de)	2006-07-20	Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
ATE350030T1 (de)	2007-01-15	Nordihydroguaiaretinsäurederivate zur behandlung von tumoren
BR0209149A (pt)	2004-07-13	Ftalazinonas
NO20034311D0 (no)	2003-09-26	CCR5-antagonister for behandling av AIDS
ATE380816T1 (de)	2007-12-15	Substituierte imidazopyrimidine zur prävention und behandlung von krebs
MA28394B1 (fr)	2007-01-02	Derives d'heteroaryle pour traitement des virus
DE602004006118D1 (de)	2007-06-06	2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
ATE419242T1 (de)	2009-01-15	Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
DE50205466D1 (de)	2006-02-02	Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
ATE428712T1 (de)	2009-05-15	4-amino-5-oxo-8-phenyl-5h-pyrido-ä2,3-dü- pyrimidin-derivate als inhibitoren der tyrosinkinasen und der raf-kinasen zur behandlung von tumoren
DE60316128D1 (de)	2007-10-18	N-sulfonylurea-apoptosis-förderer
DE60233740D1 (de)	2009-10-29	Benzoägüchinolinderivate zur behandlung von glaucom und kurzsichtigkeit
ATE353693T1 (de)	2007-03-15	Neue piperazinyl-pyrazinon-derivate zur behandlung von 5-ht2a rezeptor-bedingten erkrankungen
DE60326348D1 (de)	2009-04-09	Makrozyclen zur behandlung von krebserkrankungen